Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish.
Prog Neuropsychopharmacol Biol Psychiatry · 2021
Last updated 2026-05-28In a study on zebrafish, the GLP-1 drug liraglutide reduced anxiety-like behaviors after a single dose and prevented stress-related changes in behavior and brain chemistry when given over time. The research suggests liraglutide may have effects on the brain that could help counteract stress, but more studies are needed to understand its potential for treating brain disorders.
AI summary of the abstract below.
| Journal | Prog Neuropsychopharmacol Biol Psychiatry, 2021 |
|---|---|
| Citations | 14 |
| Relative citation ratio | 1.29 |
| NIH percentile | 59 |
| Molecules | liraglutide |
Abstract
Stress-related disorders are extremely harmful and cause significant impacts on the individual and society. Despite the limited evidence regarding glucagon-like peptide-1 receptor (GLP-1R) and mental disorders, a few clinical and preclinical studies suggest that modulating this system could improve symptoms of stress-related disorders. This study aimed to investigate the effects of liraglutide, a GLP-1R agonist, on neurobehavioral phenotypes and brain oxidative status in adult zebrafish. Acute liraglutide promoted anxiolytic-like effects in the light/dark test, while chronic treatment blocked the impact of unpredictable chronic stress on behavioral and physiological parameters. Taken together, our study demonstrates that liraglutide is active on the zebrafish brain and may counteract some of the effects induced by stress. More studies are warranted to further elucidate the potential of GLP-1R agonists for the management of brain disorders.
Verbatim abstract via PubMed 34147534 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.